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The genus Enterovirus, belonging to the family Picornaviridae, includes well-known pathogens, such as
poliovirus, coxsackievirus, and rhinovirus. Brefeldin A (BFA) impedes replication of several enteroviruses
through inhibition of Golgi-specific BFA resistance factor 1 (GBF1), a regulator of secretory pathway integrity
and transport. GBF1 mediates the GTP exchange of Arf1, which in activated form recruits coatomer protein
complex I (COP-I) to Golgi vesicles, a process important in transport between the endoplasmic reticulum and
Golgi vesicles. Recently, the drugs AG1478 and Golgicide A (GCA) were put forward as new inhibitors of GBF1.
In this study, we investigated the effects of these putative GBF1 inhibitors on secretory pathway function and
enterovirus replication. We show that both drugs induced fragmentation of the Golgi vesicles and caused
dissociation of Arf1 and COP-I from Golgi membranes, yet they differed in their effect on GBF1 localization.
The effects of AG1478, but not those of GCA, could be countered by overexpression of Arf1, indicating a
difference in their molecular mechanism of action. Consistent with this idea, we observed that GCA drastically
reduced replication of coxsackievirus B3 (CVB3) and other human enterovirus species, whereas AG1478 had
no effect at all on enterovirus replication. Time-of-addition studies and analysis of RNA replication using a
subgenomic replicon both showed that GCA suppresses RNA replication of CVB3, which could be countered
by overexpression of GBF1. These results indicate that, in contrast to AG1478, GCA inhibits CVB3 RNA
replication by targeting GBF1. AG1478 and GCA may be valuable tools to further dissect enterovirus
replication.
The Enterovirus genus, belonging to the Picornaviridae fam-
ily, includes many important human pathogens, such as polio-
virus, human rhinovirus, echovirus, and coxsackievirus. These
are small, nonenveloped viruses that contain a single-stranded
RNA genome of positive polarity. The genome is approxi-
mately 7.5 kb in length and encodes a single large polyprotein,
which is processed into capsid proteins, encoded in the P1
region, and the nonstructural P2 and P3 region proteins that
mediate viral RNA replication.
Brefeldin A (BFA), a fungal metabolite, is a well-known
inhibitor of enteroviruses. BFA blocks transport of cargo
from the endoplasmic reticulum (ER) to the Golgi vesicles
by disrupting the Golgi vesicles and ER-Golgi intermediate
compartment (ERGIC) integrity through inhibition of sev-
eral guanine nucleotide exchange factors (GEFs), including
Golgi-specific BFA resistance factor 1 (GBF1), BFA-inhib-
ited GEF 1 (BIG1), and BIG2 (3, 18). These GEFs regulate
the activity of GTPase ADP-ribosylation factor 1 (Arf1) by
stimulating GTP exchange. Upon activation, Arf1-GTP binds
to Golgi membranes where it induces formation of secretory
vesicles via recruitment of coatomer protein complex I (COP-
I), a coatomer protein involved in the transport between the
Golgi vesicles and the ER. The inhibitory effect of BFA on
enterovirus replication is attributed to the inhibition of GBF1
and does not seem to involve BIG1 or BIG2 (2, 11). Besides
enteroviruses, other plus-strand RNA viruses, such as mouse
hepatitis virus and hepatitis C virus, also seem to rely on GBF1
for efficient replication (2, 8, 11, 21). The viral protein 3A of
the enteroviruses poliovirus and coxsackievirus B3 (CVB3) has
been shown to interact directly with GBF1 (22, 22a, 23), but
the exact function of this interaction remains to be established.
Recently, two compounds, AG1478 and Golgicide A
(GCA), have been proposed to specifically inhibit GBF1.
AG1478 was identified by screening a library of compounds for
their ability to induce Golgi complex disassembly (13).
AG1478, known as an inhibitor of the epidermal growth factor
receptor (EGFR), had effects on the Golgi membranes highly
similar to those of BFA through a mechanism not involving the
inhibition of EGFR. Arf1-GTP pulldown assays showed that
AG1478 inhibited Arf1 activation. Furthermore, overexpres-
sion of GBF1 was shown to counter the effect of AG1478 on
COP-I localization. Based on these results, AG1478 was pro-
posed to be a GBF1 inhibitor.
GCA was identified in a high-throughput screen for small
molecules that protected Vero cells from the effects of Shiga
toxin (15). Similar to AG1478 and BFA, GCA was reported to
fragment the Golgi vesicles and to inhibit Arf1 activation.
Furthermore, overexpression of either wild-type GBF1 or the
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BFA-resistant mutant GBF1-M832L relieved the effects of
GCA. In addition, the authors constructed a structural model
of the catalytic Sec7 domain of GBF1 in complex with GCA,
showing that GCA binds GBF1 at the same site as BFA.
Collectively, their results provided convincing lines of evidence
that GCA specifically inhibits GBF1 in a manner similar to
BFA and does not act on BIG1 and BIG2.
BFA has been instrumental in elucidating the membrane
requirements for enterovirus replication. Therefore, we inves-
tigated the effects of AG1478 and GCA on enterovirus repli-
cation after first characterizing the effects of these drugs on
BGM cells, the cell line that we routinely use in our studies on
coxsackievirus B3 replication. Treatment with other AG1478
or GCA fragmented the Golgi vesicles and caused dissociation
of Arf1 and COP-I from Golgi membranes, yet these drugs had
different effects on GBF1 localization. Interestingly, the effects
of AG1478, but not those of GCA, could be countered by
overexpression of Arf1. Next, GCA was found to abrogate
enterovirus replication, whereas surprisingly AG1478 did not
affect replication at all. Together these results indicate that
AG1478 on one hand and GCA and BFA on the other hand
have different mechanisms of action, leading to a disparate
effect on enterovirus replication.
MATERIALS AND METHODS
Cells and reagents. Buffalo green monkey (BGM) kidney cells, HeLa cells,
and baby hamster kidney 21 (BHK-21) cells were grown at 37°C in minimal
essential medium (MEM) (Gibco) supplemented with 10% fetal bovine serum
(FBS), penicillin, and streptomycin. Brefeldin A (BFA) (Sigma-Aldrich) was
dissolved in methanol, and dimethyl sulfoxide (DMSO) was used to dissolve
AG1478 (Sigma-Aldrich) and Golgicide A (GCA) (15). Unless indicated other-
wise, the concentrations of BFA, AG1478, and GCA used in experiments were
2 g/ml (7.1 M), 25 M, and 10 M, respectively.
Viruses. Coxsackievirus B3 (CVB3) was obtained by transfecting in vitro-
transcribed RNA derived from the p53CB3/T7 plasmid. This plasmid contains
the cDNA of CVB3 strain Nancy driven by a T7 RNA polymerase promoter (24).
The encephalomyocarditis virus (EMCV) strain used in this study is the men-
govirus strain, which was obtained upon transfection of in vitro-transcribed RNA
from cDNA clone pM16.1 (6). Enterovirus 71 (EV71) (BrCr) and coxsackievirus
A21 (CVA21) (Coe) were obtained from the National Institute for Public Health
and Environment (RIVM, Netherlands).
Plasmids. The VSVG-GFP plasmid, kindly provided by P. Keller and K.
Simons (Max Planck Institute of Molecular Biology and Genetics, Dresden,
Germany), encodes a green fluorescent protein (GFP) fusion of the tempera-
ture-sensitive ts045 vesicular stomatitis virus G protein (VSV-G protein) (19).
The plasmid coding for Gaussia luciferase, pCMV-Gluc (CMV stands for cyto-
megalovirus, and Gluc stands for Gaussia luciferase), and the control plasmid,
pEGFP-C1 (EGFP stands for enhanced GFP), were purchased from New En-
gland Biolabs and Clontech, respectively. Plasmids pEYFP-GBF1 wt (EYFP
stands for enhanced yellow fluorescent protein, and wt stands for wild type),
pEYFP-GBF1-M832L (12), pArf1-EGFP wt (5), and pArf1-Q71L-EGFP (11)
were described previously. DNA transfections were performed with 200 ng plas-
mid DNA and the transfection reagent Fugene (Roche) according to the man-
ufacturer’s instructions 1 day prior to the assays.
VSV-G trafficking. BGM cells grown on coverslips in 24-well plates were
transfected with pVSVG3(ts045)-GFP and incubated at 40°C. At 16 h posttrans-
fection, BFA, AG1478, or GCA was added to the cells. Following a 30-min
incubation, the temperature was switched to 32°C. After 2 h, the cells were fixed,
stained with anti-GFP antibody (diluted 1:100; Molecular Probes) and Alexa
Fluor 488-conjugated anti-mouse immunoglobulin G (IgG) (diluted 1:500, Mo-
lecular Probes), and analyzed with a Leica BMR microscope.
Gaussia luciferase secretion assay. At 16 h posttransfection with pCMV-Gluc,
BGM cells were treated with BFA, AG1478, or GCA for 2.5 h. Subsequently, the
supernatant was analyzed for luciferase activity with a Renilla luciferase assay kit
(Promega).
Immunofluorescence. BGM cells grown to subconfluency on coverslips in
24-well plates were treated with BFA, AG1478, or GCA for 1 h at 37°C. After
fixation with 4% paraformaldehyde, the cells were stained with polyclonal anti-
COP-I (against - and -COP) antiserum (diluted 1:200; from K. Frey and F.
Wieland, Biochemie-Zentrum, Heidelberg, Germany), monoclonal anti-GBF1
antibody (1:100, BD Biosciences), monoclonal anti-GM130 antibody (1:200, BD
Biosciences), or polyclonal anti-Arf1 antibody (1:150, from B. Helms, Bioche-
mie-Zentrum, Heidelberg, Germany). The samples were stained with the sec-
ondary antibodies Alexa Fluor 594-conjugated goat anti-rabbit IgG and Alexa
Fluor 488-conjugated anti-mouse IgG (Molecular Probes) and analyzed with a
Leica BMR microscope.
Virus infections. Replication of CVB3 and EV71 was studied on subconfluent
layers of BGM cells, while CVA21 and mengovirus were studied on HeLa and
BHK-21 cells, respectively. After 30 min of virus adsorption, the cells were
washed, and fresh (drug-containing) medium was added to the cells. For the
time-of-addition studies, GCA was added to the cells at 1-h intervals. At 8 hours
postinfection (h.p.i.), the cells were freeze-thawed three times to release intra-
cellular virus particles, and virus titers were determined by endpoint titration by
the method of Reed and Muench and expressed as 50% cell culture infective
doses (CCID50) per ml (14).
Replicon assay. Replicon assays were performed as described previously (20).
The p53CB3-LUC subgenomic replicon used contains the CVB3 cDNA in which
the P1 capsid coding region is replaced by the firefly luciferase gene (24). The
plasmid was linearized, purified, and transcribed in vitro by T7 RNA polymerase,
and transcript RNAs were transfected into BGM cells. After transfection, the cells
were cultured in the presence or absence of drugs at 37°C. At 2, 4, 6, and 8 h
posttransfection, the cells were lysed and analyzed for firefly luciferase activity.
Analysis of viral polyprotein processing in vivo. In vivo labeling studies were
performed as described previously (4). Briefly, BGM cells in a 24-well plate were
infected with CVB3 at a multiplicity of infection (MOI) of 50. At 5 h.p.i., the cells
were starved by incubating them in methionine-free medium for 30 min. Subse-
quently, 35S-labeled methionine was added for 30 min. At 6 h.p.i., the cells were
lysed, and translation products were analyzed on a 10% polyacrylamide gel
containing SDS, fixed, and then exposed to Kodak XAR film.
RESULTS AND DISCUSSION
AG1478 and GCA inhibit cargo transport through the se-
cretory pathway. We determined the effects of the putative
Golgi-specific BFA resistance factor 1 (GBF1) inhibitors
AG1478 and Golgicide A (GCA) on the function of the secre-
tory pathway in BGM cells, the cell line that we routinely use
in our studies on enterovirus replication. First, we investigated
the transport of the membrane-associated VSV-G protein by
use of a temperature-sensitive mutant that is retained in the
ER at a temperature of 40°C. When the temperature is
switched to 32°C, the VSV-G protein is allowed to progress
further along the secretory pathway to the plasma membrane
(Fig. 1A). In BFA-treated cells, the VSV-G protein was absent
from the plasma membrane after the temperature switch. In-
stead, it displayed a reticular and punctate staining which was
previously identified to be the ER and ER exit sites (23).
Treatment with either AG1478 or GCA had a similar effect,
indicating that all drugs tested inhibit transport of membrane-
bound proteins.
Second, we tested the effects of the drugs on secretion of
soluble proteins by use of Gaussia luciferase (Gaussia-luc), a
novel form of luciferase that is secreted by the cells in the
supernatant (1, 16). At 16 h after transfection of BGM cells
with pCMV-Gluc, the medium was replaced, and drugs were
added to the cells. After 2.5 h, the supernatant was analyzed
for Gaussia-luc activity. The supernatant of untreated cells
exhibited high luciferase activity, whereas a severe decrease in
luciferase activity was detected upon treatment with BFA,
AG1478, or GCA (Fig. 1B).
Together, these results show that, similar to BFA, AG1478
and GCA inhibit transport of both membrane-anchored pro-
teins and secreted soluble factors.
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AG1478 and GCA cause Golgi dispersal and inhibit COP-I
recruitment. Next, we determined the effects of AG1478 and
GCA on the Golgi integrity and localization of GBF1, Arf1,
and COP-I in BGM cells. All drugs caused Golgi dispersal as
shown by the fragmented localization of cis-Golgi matrix pro-
tein GM130 after a 1-h treatment (Fig. 1C). In untreated cells,
GBF1, the putative target of the drugs, is localized to the Golgi
apparatus (Fig. 1C). Upon addition of BFA or GCA, GBF1
FIG. 1. AG1478 and GCA disturb the secretory pathway. (A) BGM cells were transfected with pVSVG3(ts045)-GFP, a construct encoding a
temperature-sensitive GFP-tagged mutant of the VSV-G protein, and incubated at 40°C. At this temperature, the VSV-G protein is folded
incorrectly and retained in the ER. At 30 min after the addition of BFA, AG1478, or GCA, the temperature was switched to the permissive
temperature of 32°C for 2 h, which allows the VSV-G protein to fold properly and traffic through the secretory pathway to the plasma membrane.
(B) Cells expressing Gaussia luciferase (Gaussia-luc) were treated with BFA, AG1478, or GCA for 2.5 h. Subsequently, the medium was analyzed
for luciferase activity. The experiment was performed in triplicate, and the bars represent means  standard error of the means (SEMs) (error
bars). Upon drug treatment, a significant reduction in luciferase activity was detected in comparison with untreated cells () (P  0.001, Student’s
t test). (C) BGM cells were treated with AG1478, GCA, or BFA for 1 h, after which cells were fixed and stained with antibodies against GBF1,
Arf1, COP-I, or GM130.
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redistributed to a more diffuse localization. In contrast, GBF1
displayed a punctate pattern in AG1478-treated cells. Al-
though AG1478 and GCA had a different effect on GBF1
localization, they had similar effects on Arf1 and COP-I local-
ization. Arf1 and COP-I localized to the Golgi apparatus in
untreated BGM cells, but drug-treated cells displayed a diffuse
staining of Arf1 and COP-I with no apparent difference be-
tween the drugs (Fig. 1C).
The effects of GCA can be countered only by overexpression
of GBF1, while the effects of AG1478 can also be countered by
overexpression of Arf1. Previously it was shown that the effect
of BFA on COP-I can be countered by overexpressing GBF1
(3, 10, 12) and that the BFA-resistant GBF1-M832L mutant
was even more effective (12). This mutant was also reported to
confer resistance to GCA (15). To test the ability of GBF1 to
counter drug-induced COP-I dissociation, cells overexpressing
GBF1 or Arf1 were treated for 1 h with the different drugs,
after which COP-I was stained. Figure 2A shows that COP-I
was present on membranes in drug-treated cells that overex-
press yellow fluorescent protein (YFP)-tagged GBF1 (GBF1-
YFP), while COP-I appeared cytosolic in untransfected, drug-
treated cells. Also, the Golgi apparatus morphology seemed to
be restored in the drug-treated, transfected cells with GBF1-
YFP localizing to the Golgi apparatus. Thus, expression of
GBF1 was indeed able to prevent the dissociation of COP-I
from membranes induced by the different drugs. Overexpres-
sion of GBF1-M832L showed similar results (data not shown).
In addition, we tested whether overexpression of Arf1, the
effector of GBF1, was able to counter the effects of the drugs
on COP-I localization. Figure 2A shows that in cells treated
FIG. 2. Overexpression of GBF1 counters the effects of BFA, GCA, and AG1478, while overexpression of Arf1 counters only the effects of
AG1478. (A) Plasmids encoding GBF1 or Arf1 were transfected into BGM cells. At 24 h posttransfection, the cells were treated for 1 h with BFA,
AG1478, or GCA. Subsequently, the cells were fixed and stained with an antibody against COP-I. GBF1-wt, wild-type GBF1. (B) A Gaussia-luc
construct was cotransfected with GBF1-M832L or Arf1 constructs into cells. The next day, the medium was replaced with (drug-containing)
medium, and after 2.5 h, the supernatant was analyzed for luciferase activity. Gaussia-luc activity is expressed as a percentage of luciferase activity
in the supernatant of untreated cells. The experiment was performed in triplicate, and the bars represent means  SEMs (error bars).
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with either BFA or GCA, both COP-I and the overexpressed
Arf1-GFP have a diffuse distribution, indicating that the
effects of BFA or GCA could not be countered by overex-
pression of wild-type Arf1, which is consistent with previous
observations (17). The constitutively active mutant Arf1-
Q71L was also not able to counteract the effects of BFA and
GCA (data not shown). Surprisingly, overexpression of Arf1
did counter the effects of AG1478 on COP-I localization,
since COP-I localized to Arf1-GFP-containing membranes
in transfected cells.
Next, we examined whether overexpression of GBF1-M832L
or Arf1 could relieve the effects of the drugs on a functional
level by measuring the secretion of Gaussia-luc. Gaussia-luc
secretion was inhibited by all three drugs, but in all cases this
effect could be countered by overexpression of GBF1-M832L
(Fig. 2B). The inhibitory effect of AG1478, but not that of BFA
or GCA, could be relieved by overexpressing Arf1 or, to a
stronger extent, by overexpressing the Arf1-Q71L mutant (Fig.
2B). Collectively, these results imply that AG1478 has a dif-
ferent mechanism of action than BFA and GCA.
GCA, but not AG1478, inhibits enterovirus replication.
GBF1 is a crucial factor for the replication of enteroviruses
(2, 11). Therefore, we tested whether AG1478 and GCA
were able to inhibit replication of coxsackievirus B3
(CVB3), a human enterovirus B species (HEV-B species)
member. A representative growth curve of CVB3 is shown in
Fig. 3A, which shows that virus production reaches a plateau
after about 8 h. Therefore, we evaluated the effects of
AG1478 and GCA on CVB3 replication by determining the
virus yield at 8 h.p.i. Interestingly, AG1478 did not inhibit
replication of CVB3, not even in concentrations higher than
those required for fragmentation of the Golgi apparatus
(Fig. 3B). GCA, however, impaired CVB3 replication as
shown in Fig. 3C. Concentrations of 1 or 3 M GCA had no
effect on the virus yield, but with 10 M GCA, the concen-
tration used by Sae´nz et al. (15) which also in our hands had
a very strong effect on BGM cells, virus replication was
strongly inhibited. Virus replication was completely abol-
ished in the presence of 30 M GCA with virus yields being
similar to input levels. As GCA has been reported to spe-
cifically inhibit GBF1 and not the other guanine nucleotide
exchange factors (GEFs), such as BIG1 and BIG2 (15),
these results provide further evidence that GBF1 is the only
GEF that is required for enterovirus replication.
FIG. 3. GCA, not AG1478, inhibits replication of enteroviruses. (A) BGM cells were infected with CVB3 at an MOI of 5. Total virus titers were
determined at the indicated time points. The virus titer was measured as log 50% cell culture infective doses per ml (log CCID50/ml). (B) Various
concentrations of AG1478 were added to the cells immediately after infection with CVB3. Virus titers were determined after 8 h. (C) The cells
were infected with CVB3 and treated with various concentrations of GCA. Concentrations of 10 M GCA or higher significantly inhibited CVB3
replication (P  0.001, one-way analysis of variance [ANOVA]). (D) BGM, HeLa, or BHK-21 cells were infected with CVB3, EV71, CVA21, or
mengovirus and treated with GCA or BFA. Virus titers were determined after 8 h. Experiments were performed in triplicate, and the bars
represent means  SEMs (error bars).
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The spectrum of GCA activity on replication of picornavi-
ruses was examined by testing its effect on two other entero-
virus species: enterovirus 71 (EV71), a member of the HEV-A
species, and coxsackievirus A21 (CVA21), a member of the
HEV-C species. In addition, we tested whether mengovirus, a
member of the cardiovirus genus known to be resistant to BFA
(7, 9), is sensitive to treatment with GCA. BGM cells (CVB3/
EV71), HeLa cells (CVA21), and BHK-21 cells (mengovirus)
were infected with the different viruses and incubated in the
presence or absence of GCA. We determined the virus yield
after 8 h, since at later time points (determined at 16 h), we
observed partial recovery of the Golgi structure and the GBF1
localization (data not shown), which might be caused by me-
tabolism of GCA or alternatively by a cellular compensatory
mechanism. Consistent with this observation, the inhibition of
CVB3 replication by GCA was also somewhat decreased after
16 h as measured by virus growth curves (data not shown),
providing further evidence for a correlation between enterovi-
rus replication and GBF1 activity.
Figure 3D shows that besides CVB3, the two other entero-
viruses tested (EV71 and CVA21) also showed sensitivity to
GCA. Mengovirus, on the other hand, was resistant to GCA
and replicated to titers in the presence of GCA that were
similar to the titers in the absence of this drug in both BHK-21
cells (Fig. 3D) and HeLa cells (data not shown). Taken to-
gether, these results show that the antiviral activity of GCA is
strongly reminiscent of that of BFA, which supports the idea
that GCA targets GBF1 and thereby inhibits virus replication
in a manner similar to BFA.
GCA impairs enterovirus RNA replication by targeting
GBF1. To investigate which stage of the virus life cycle is
inhibited by GCA, we first performed time-of-addition studies,
FIG. 4. GCA inhibits enterovirus RNA replication by targeting GBF1. (A) BGM cells were infected with CVB3 at an MOI of 5. GCA was
added to the cells at 1-h intervals, and virus yields were determined after 8 h. (B) Cells were transfected with RNA in vitro transcribed from the
p53CB3-LUC subgenomic replicon and subsequently treated with GCA or BFA. At 2, 4, 6, or 8 h.p.i., the cells were lysed, and firefly luciferase
activity (in relative light units [RLU]) was determined as a measure of RNA replication. (C) BGM cells were infected with CVB3 at an MOI of
50. At 5.5 h.p.i., the cells were starved in methionine-free medium, and then [35S]methionine and drugs were added to the cells. After 30 min, cells
were lysed and proteins were analyzed by SDS-PAGE. (D) Cells transfected with plasmids encoding GBF1-M832L or EGFP as a negative control
were infected with CVB3 in the presence of 2 g/ml BFA, 10 M GCA, or 30 M GCA or in the absence of drugs. Virus yields were determined
at 8 h.p.i. The experiment was performed in triplicate, and bars represent means  SEMs.
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in which we added GCA to the cells after infection with CVB3
at 1-h intervals and determined the virus yield at 8 h.p.i. The
life cycle of picornaviruses is rapid, with virus entry, uncoating,
and translation occurring within 2 h.p.i., while viral RNA rep-
lication is initiated at 2.5 to 3 h.p.i. Virus production starts at
5 to 6 h.p.i (Fig. 3D) and reaches a plateau after approximately
8 h.p.i (25). Figure 4A shows that GCA lost its efficacy when
added later than 4 h after infection, which suggests that the
drug exerts its effect in the stage of viral protein translation and
viral RNA replication. If the drug was targeting either virus
entry or assembly, it would have exerted its effect when added
early (0 to 2 h.p.i) or late (5 to 7 h.p.i), respectively.
In vivo labeling studies were performed to examine the pos-
sibility that GCA impairs translation or processing of the viral
proteins. To this end, BGM cells were infected with CVB3 in
the absence of drugs. At 5.5 h.p.i., a time point when there is
efficient virus replication, BGM cells were pulse-labeled for 30
min with [35S]methionine. During these 30 min, drugs were
also added to the cells to test possible effects on viral protein
synthesis and processing in a situation where only viral proteins
are translated due to host shutdown. Neither GCA nor BFA
affected translation or processing of viral proteins (Fig. 4C).
Subsequently, the effect of GCA on RNA replication was
studied directly by use of a subgenomic replicon pCB3/T7-Luc,
in which the P1 region has been replaced with the firefly lucif-
erase gene. The level of luciferase activity in cells is a measure
of viral RNA replication. Figure 4B shows that, similar to BFA,
GCA strongly inhibits firefly luciferase accumulation, demon-
strating that GCA hinders viral RNA replication.
Since the dissociation of COP-I from Golgi membranes in-
duced by GCA could be countered by overexpression of GBF1
or GBF1-M832L, we tested whether GBF1-M832L overex-
pression was also able to counter virus replication in the pres-
ence of GCA. To this end, BGM cells overexpressing GBF1-
M832L or EGFP as a negative control were infected with
CVB3, and virus titers were determined at 8 h.p.i. Overexpres-
sion of GBF1-M832L had no effect on CVB3 replication in
untreated cells. However, in the presence of 10 M GCA or 2
g/ml BFA, virus titers were significantly higher in cells over-
expressing GBF1-M832L than in EGFP-expressing cells (Fig.
4D). Similar results were obtained with 30 M GCA, a con-
centration that completely blocked CVB3 replication, indicat-
ing that GBF1-M832L was able to relieve the effect of the
drugs on CVB3 replication.
Concluding remarks. In this study, we showed that AG1478,
GCA, and BFA all inhibited the function of the secretory
pathway as shown by defective transport of VSV-G protein and
Gaussia-luc. The drugs fragmented the Golgi membranes and
dispersed Arf1 and COP-I in a similar manner, but they dif-
fered in their effects on the localization of GBF1. Further-
more, overexpression of Arf1 could counter the effect of
AG1478, but not of GCA or BFA, on COP-I localization and
function of the secretory pathway. Finally, unlike GCA,
AG1478 did not inhibit replication of enteroviruses, which is
known to be GBF1 dependent (2, 11). Together, these results
question whether AG1478 is a genuine inhibitor of GBF1.
Remarkably, AG1478 did not inhibit enterovirus replication,
despite the fact that it has many effects in common with BFA
and GCA, such as inhibition of the secretory pathway, disas-
sembly of the ER-Golgi intermediate compartment (ERGIC)
and the Golgi apparatus, and dispersal of Arf1 and COP-I.
This observation strongly suggests that the inhibitory effect of
BFA and GCA on GBF1 function and/or its localization is
crucial to suppress CVB3 RNA replication.
In sum, AG1478 and GCA disturb the secretory route in a
different manner. Thereby, these drugs may be useful new
tools to study enterovirus replication.
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